Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, E. A.
Right arrow Articles by Shapiro, A.M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, E. A.
Right arrow Articles by Shapiro, A.M. J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:710-719, 2001
© 2001 by the American Diabetes Association, Inc.

Clinical Outcomes and Insulin Secretion After Islet Transplantation With the Edmonton Protocol

Edmond A. Ryan1, Jonathan R.T. Lakey2, Ray V. Rajotte2, Gregory S. Korbutt2, Tatsuya Kin2, Sharleen Imes4, Alex Rabinovitch1, John F. Elliott3, David Bigam2, Norman M. Kneteman2, Garth L. Warnock2, Ingrid Larsen4, and A.M. James Shapiro2

1 Department of Medicine, the
2 Department of Surgery, Surgical Medical Research Institute, and the
3 Department of Medical Microbiology and Infectious Diseases, University of Alberta
4 Capital Health Authority, Edmonton, Alberta

Islet transplantation offers the prospect of good glycemic control without major surgical risks. After our initial report of successful islet transplantation, we now provide further data on 12 type 1 diabetic patients with brittle diabetes or problems with hypoglycemia previous to 1 November 2000. Details of metabolic control, acute complications associated with islet transplantation, and long-term complications related to immunosuppression therapy and diabetes were noted. Insulin secretion, both acute and over 30 min, was determined after intravenous glucose tolerance tests (IVGTTs). The median follow-up was 10.2 months (CI 6.5–17.4), and the longest was 20 months. Glucose control was stable, with pretransplant fasting and meal tolerance–stimulated glucose levels of 12.5 ± 1.9 and 20.0 ± 2.7 mmol/l, respectively, but decreased significantly, with posttransplant levels of 6.3 ± 0.3 and 7.5 ± 0.6 mmol/l, respectively (P < 0.006). All patients have sustained insulin production, as evidenced by the most current baseline C-peptide levels 0.66 ± 0.06 nmol/l, increasing to 1.29 ± 0.25 nmol/l 90 min after the meal-tolerance test. The mean HbA1c level decreased from 8.3 ± 0.5% to the current level of 5.8 ± 0.1% (P < 0.001). Presently, four patients have normal glucose tolerance, five have impaired glucose tolerance, and three have post–islet transplant diabetes (two of whom need oral hypoglycemic agents and low-dose insulin (<10 U/day). Three patients had a temporary increase in their liver-function tests. One patient had a thrombosis of a peripheral branch of the right portal vein, and two of the early patients had bleeding from the hepatic needle puncture site; but these technical problems were resolved. Two patients had transient vitreous hemorrhages. The two patients with elevated creatinine levels pretransplant had a significant increase in serum creatinine in the long term, although the mean serum creatinine of the group was unchanged. The cholesterol increased in five patients, and lipid-lowering therapy was required for three patients. No patient has developed cytomegalovirus infection or disease, posttransplant lymphoproliferative disorder, malignancies, or serious infection to date. None of the patients have been sensitized to donor antigen. In 11 of the 12 patients, insulin independence was achieved after 9,000 islet equivalents (IEs) per kilogram were transplanted. The acute insulin response and the insulin area under the curve (AUC) after IVGTT were consistently maintained over time. The insulin AUC from the IVGTT correlated to the number of islets transplanted, but more closely correlated when the cold ischemia time was taken into consideration (r = 0.83, P < 0.001). Islet transplantation has successfully corrected labile type 1 diabetes and problems with hypoglycemia, and our results show persistent insulin secretion. After a minimum of 9,000 IEs per kilogram are provided, insulin independence is usually attained. An elevation of creatinine appears to be a contraindication to this immunosuppressive regimen. For the subjects who had labile type 1 diabetes that was difficult to control, the risk-to-benefit ratio is in favor of islet transplantation.

Abbreviations: AIRg, acute insulin response to glucose; AUC, area under the curve, AUCC-p, AUC for C-peptide above baseline; AUCg, AUC for glucose above baseline; AUCi, AUC for insulin above baseline; CMV, cytomegalovirus; HOMA, homeostasis model assessment; IE, islet equivalent; IGT, impaired glucose tolerance; IVGTT, intravenous glucose tolerance test; KG, the rate of glucose disposal; OGTT, oral glucose tolerance test; MAGE, mean amplitude of glycemic excursion; WBC, white blood cell count


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
J. A. Schlechte
Update in Endocrinology
Ann Intern Med, October 16, 2007; 147(8): 563 - 572.
[Full Text] [PDF]

Home page
 DiabetesHome page
S. Cabric, J. Sanchez, T. Lundgren, A. Foss, M. Felldin, R. Kallen, K. Salmela, A. Tibell, G. Tufveson, R. Larsson, et al.
Islet Surface Heparinization Prevents the Instant Blood-Mediated Inflammatory Reaction in Islet Transplantation
Diabetes, August 1, 2007; 56(8): 2008 - 2015.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
P. Maffi, F. Bertuzzi, F. De Taddeo, P. Magistretti, R. Nano, P. Fiorina, A. Caumo, P. Pozzi, C. Socci, M. Venturini, et al.
Kidney Function After Islet Transplant Alone in Type 1 Diabetes: Impact of immunosuppressive therapy on progression of diabetic nephropathy
Diabetes Care, May 1, 2007; 30(5): 1150 - 1155.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. D. Rivas-Carrillo, A. Soto-Gutierrez, N. Navarro-Alvarez, H. Noguchi, T. Okitsu, Y. Chen, T. Yuasa, K. Tanaka, M. Narushima, A. Miki, et al.
Cell-Permeable Pentapeptide V5 Inhibits Apoptosis and Enhances Insulin Secretion, Allowing Experimental Single-Donor Islet Transplantation in Mice
Diabetes, May 1, 2007; 56(5): 1259 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
P Srinivasan, G C Huang, S A Amiel, and N D Heaton
Islet cell transplantation
Postgrad. Med. J., April 1, 2007; 83(978): 224 - 229.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Lehmann, R. A. Zuellig, P. Kugelmeier, P. B. Baenninger, W. Moritz, A. Perren, P.-A. Clavien, M. Weber, and G. A. Spinas
Superiority of Small Islets in Human Islet Transplantation
Diabetes, March 1, 2007; 56(3): 594 - 603.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. Bertuzzi and C. Ricordi
Prediction of Clinical Outcome in Islet Allotransplantation
Diabetes Care, February 1, 2007; 30(2): 410 - 417.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Keymeulen, P. Gillard, C. Mathieu, B. Movahedi, G. Maleux, G. Delvaux, D. Ysebaert, B. Roep, E. Vandemeulebroucke, M. Marichal, et al.
Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft
PNAS, November 14, 2006; 103(46): 17444 - 17449.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A.M. J. Shapiro, C. Ricordi, B. J. Hering, H. Auchincloss, R. Lindblad, R. P. Robertson, A. Secchi, M. D. Brendel, T. Berney, D. C. Brennan, et al.
International Trial of the Edmonton Protocol for Islet Transplantation.
N. Engl. J. Med., September 28, 2006; 355(13): 1318 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. S. Narang and R. I. Mahato
Biological and biomaterial approaches for improved islet transplantation.
Pharmacol. Rev., June 1, 2006; 58(2): 194 - 243.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S.-H. Ihm, I. Matsumoto, T. Sawada, M. Nakano, H. J. Zhang, J. D. Ansite, D. E.R. Sutherland, and B. J. Hering
Effect of donor age on function of isolated human islets.
Diabetes, May 1, 2006; 55(5): 1361 - 1368.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Dombrowski, C. Mathieu, and M. Evert
Hepatocellular Neoplasms Induced by Low-Number Pancreatic Islet Transplants in Autoimmune Diabetic BB/Pfd Rats
Cancer Res., February 1, 2006; 66(3): 1833 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Toyofuku, Y. Yasunami, K. Nabeyama, M. Nakano, M. Satoh, N. Matsuoka, J. Ono, T. Nakayama, M. Taniguchi, M. Tanaka, et al.
Natural Killer T-Cells Participate in Rejection of Islet Allografts in the Liver of Mice
Diabetes, January 1, 2006; 55(1): 34 - 39.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Battaglia, A. Stabilini, E. Draghici, S. Gregori, C. Mocchetti, E. Bonifacio, and M.-G. Roncarolo
Rapamycin and Interleukin-10 Treatment Induces T Regulatory Type 1 Cells That Mediate Antigen-Specific Transplantation Tolerance
Diabetes, January 1, 2006; 55(1): 40 - 49.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Plesner, P. Liston, R. Tan, R. G. Korneluk, and C. B. Verchere
The X-Linked Inhibitor of Apoptosis Protein Enhances Survival of Murine Islet Allografts
Diabetes, September 1, 2005; 54(9): 2533 - 2540.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
G. L. Warnock, R. M. Meloche, D. Thompson, R. J. Shapiro, M. Fung, Z. Ao, S. Ho, Z. He, L.-J. Dai, L. Young, et al.
Improved Human Pancreatic Islet Isolation for a Prospective Cohort Study of Islet Transplantation vs Best Medical Therapy in Type 1 Diabetes Mellitus
Arch Surg, August 1, 2005; 140(8): 735 - 744.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. A. Ryan, B. W. Paty, P. A. Senior, D. Bigam, E. Alfadhli, N. M. Kneteman, J. R.T. Lakey, and A.M. J. Shapiro
Five-Year Follow-Up After Clinical Islet Transplantation
Diabetes, July 1, 2005; 54(7): 2060 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. Rao, J. Roccisana, K. K. Takane, R. Bottino, A. Zhao, M. Trucco, and A. Garcia-Ocana
Gene Transfer of Constitutively Active Akt Markedly Improves Human Islet Transplant Outcomes in Diabetic Severe Combined Immunodeficient Mice
Diabetes, June 1, 2005; 54(6): 1664 - 1675.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Johansson, A. Lukinius, L. Moberg, T. Lundgren, C. Berne, A. Foss, M. Felldin, R. Kallen, K. Salmela, A. Tibell, et al.
Tissue Factor Produced by the Endocrine Cells of the Islets of Langerhans Is Associated With a Negative Outcome of Clinical Islet Transplantation
Diabetes, June 1, 2005; 54(6): 1755 - 1762.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
N. R. Barshes, S. Wyllie, and J. A. Goss
Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts
J. Leukoc. Biol., May 1, 2005; 77(5): 587 - 597.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Kin, G. S. Korbutt, T. Kobayashi, J. M. Dufour, and R. V. Rajotte
Reversal of Diabetes in Pancreatectomized Pigs After Transplantation of Neonatal Porcine Islets
Diabetes, April 1, 2005; 54(4): 1032 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
M. Venturini, E. Angeli, P. Maffi, P. Fiorina, F. Bertuzzi, M. Salvioni, F. De Cobelli, C. Socci, L. Aldrighetti, C. Losio, et al.
Technique, Complications, and Therapeutic Efficacy of Percutaneous Transplantation of Human Pancreatic Islet Cells in Type 1 Diabetes: The Role of US
Radiology, February 1, 2005; 234(2): 617 - 624.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. R. Rickels, M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff
{beta}-Cell Function Following Human Islet Transplantation for Type 1 Diabetes
Diabetes, January 1, 2005; 54(1): 100 - 106.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
C. J Burns, S. J Persaud, and P. M Jones
Stem cell therapy for diabetes: do we need to make beta cells?
J. Endocrinol., December 1, 2004; 183(3): 437 - 443.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. N. Street, J. R.T. Lakey, A.M. J. Shapiro, S. Imes, R. V. Rajotte, E. A. Ryan, J. G. Lyon, T. Kin, J. Avila, T. Tsujimura, et al.
Islet Graft Assessment in the Edmonton Protocol: Implications for Predicting Long-Term Clinical Outcome
Diabetes, December 1, 2004; 53(12): 3107 - 3114.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. L. Contreras, C. Eckstein, C. A. Smyth, G. Bilbao, M. Vilatoba, S. E. Ringland, C. Young, J. A. Thompson, J. A. Fernandez, J. H. Griffin, et al.
Activated Protein C Preserves Functional Islet Mass After Intraportal Transplantation: A Novel Link Between Endothelial Cell Activation, Thrombosis, Inflammation, and Islet Cell Death
Diabetes, November 1, 2004; 53(11): 2804 - 2814.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Beuneu, O. Vosters, B. Movahedi, M. Remmelink, I. Salmon, D. Pipeleers, O. Pradier, M. Goldman, and V. Verhasselt
Human Pancreatic Duct Cells Exert Tissue Factor-Dependent Procoagulant Activity: Relevance to Islet Transplantation
Diabetes, June 1, 2004; 53(6): 1407 - 1411.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Bhargava, P. A. Senior, T. E. Ackerman, E. A. Ryan, B. W. Paty, J. R.T. Lakey, and A.M. J. Shapiro
Prevalence of Hepatic Steatosis After Islet Transplantation and Its Relation to Graft Function
Diabetes, May 1, 2004; 53(5): 1311 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Brissova, M. Fowler, P. Wiebe, A. Shostak, M. Shiota, A. Radhika, P. C. Lin, M. Gannon, and A. C. Powers
Intraislet Endothelial Cells Contribute to Revascularization of Transplanted Pancreatic Islets
Diabetes, May 1, 2004; 53(5): 1318 - 1325.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. P. Guignard, J. Oberholzer, P.-Y. Benhamou, S. Touzet, P. Bucher, A. Penfornis, F. Bayle, L. Kessler, C. Thivolet, L. Badet, et al.
Cost Analysis of Human Islet Transplantation for the Treatment of Type 1 Diabetes in the Swiss-French Consortium GRAGIL
Diabetes Care, April 1, 2004; 27(4): 895 - 900.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. Mattsson, L. Jansson, A. Nordin, A. Andersson, and P.-O. Carlsson
Evidence of Functional Impairment of Syngeneically Transplanted Mouse Pancreatic Islets Retrieved from the Liver
Diabetes, April 1, 2004; 53(4): 948 - 954.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. A. Ryan, T. Shandro, K. Green, B. W. Paty, P. A. Senior, D. Bigam, A.M. J. Shapiro, and M.-C. Vantyghem
Assessment of the Severity of Hypoglycemia and Glycemic Lability in Type 1 Diabetic Subjects Undergoing Islet Transplantation
Diabetes, April 1, 2004; 53(4): 955 - 962.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
N. Zhang, A. Richter, J. Suriawinata, S. Harbaran, J. Altomonte, L. Cong, H. Zhang, K. Song, M. Meseck, J. Bromberg, et al.
Elevated Vascular Endothelial Growth Factor Production in Islets Improves Islet Graft Vascularization
Diabetes, April 1, 2004; 53(4): 963 - 970.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. M. Harlan
Gene-Altered Islets for Transplant: Giant Leap or Small Step?
Endocrinology, February 1, 2004; 145(2): 463 - 466.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. A. Johnson, M. Kotovych, E. A. Ryan, and A.M. J. Shapiro
Reduced Fear of Hypoglycemia in Successful Islet Transplantation
Diabetes Care, February 1, 2004; 27(2): 624 - 625.
[Full Text] [PDF]

Home page
 DiabetesHome page
B. Nikolic, Y. Takeuchi, I. Leykin, Y. Fudaba, R. N. Smith, and M. Sykes
Mixed Hematopoietic Chimerism Allows Cure of Autoimmune Diabetes Through Allogeneic Tolerance and Reversal of Autoimmunity
Diabetes, February 1, 2004; 53(2): 376 - 383.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
J. C. Lopez-Talavera, A. Garcia-Ocana, I. Sipula, K. K. Takane, I. Cozar-Castellano, and A. F. Stewart
Hepatocyte Growth Factor Gene Therapy for Pancreatic Islets in Diabetes: Reducing the Minimal Islet Transplant Mass Required in a Glucocorticoid-Free Rat Model of Allogeneic Portal Vein Islet Transplantation
Endocrinology, February 1, 2004; 145(2): 467 - 474.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
M. G. Tal, B. Hirshberg, Z. Neeman, D. Bunnell, S. Soleimanpour, J. Bacher, N. Patterson, R. Chang, and D. M. Harlan
Induction of Diabetes in Nonhuman Primates by Means of Temporary Arterial Embolization and Selective Arterial Injection of Streptozotocin
Radiology, January 1, 2004; 230(1): 163 - 168.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Hirshberg, K. I. Rother, B. J. Digon III, J. Lee, J. L. Gaglia, K. Hines, E. J. Read, R. Chang, B. J. Wood, and D. M. Harlan
Benefits and Risks of Solitary Islet Transplantation for Type 1 Diabetes Using Steroid-Sparing Immunosuppression: The National Institutes of Health experience
Diabetes Care, December 1, 2003; 26(12): 3288 - 3295.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. J. T. Owen, E. A. Ryan, K. O'Kelly, J. R. T. Lakey, M. C. McCarthy, B. W. Paty, D. L. Bigam, N. M. Kneteman, G. S. Korbutt, R. V. Rajotte, et al.
Percutaneous Transhepatic Pancreatic Islet Cell Transplantation in Type 1 Diabetes Mellitus: Radiologic Aspects
Radiology, October 1, 2003; 229(1): 165 - 170.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Dai, Y. Li, J. Yang, and Y. Liu
Hepatocyte Growth Factor Preserves Beta Cell Mass and Mitigates Hyperglycemia in Streptozotocin-induced Diabetic Mice
J. Biol. Chem., July 11, 2003; 278(29): 27080 - 27087.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Seifarth, S. Pop, B. Liu, C. P. Wong, and R. Tisch
More Stringent Conditions of Plasmid DNA Vaccination Are Required to Protect Grafted Versus Endogenous Islets in Nonobese Diabetic Mice
J. Immunol., July 1, 2003; 171(1): 469 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
T. D. Zorina, V. M. Subbotin, S. Bertera, A. M. Alexander, C. Haluszczak, B. Gambrell, R. Bottino, A. J. Styche, and M. Trucco
Recovery of the Endogenous {beta} Cell Function in the NOD Model of Autoimmune Diabetes
Stem Cells, July 1, 2003; 21(4): 377 - 388.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Robitaille, J. Dusseault, N. Henley, L. Rosenberg, and J.-P. Halle
Insulin-Like Growth Factor II Allows Prolonged Blood Glucose Normalization with a Reduced Islet Cell Mass Transplantation
Endocrinology, July 1, 2003; 144(7): 3037 - 3045.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. F. Markmann, M. Rosen, E. S. Siegelman, M. C. Soulen, S. Deng, C. F. Barker, and A. Naji
Magnetic Resonance-Defined Periportal Steatosis Following Intraportal Islet Transplantation: A Functional Footprint of Islet Graft Survival?
Diabetes, July 1, 2003; 52(7): 1591 - 1594.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. Menasche
Cell transplantation in myocardium
Ann. Thorac. Surg., June 1, 2003; 75(90060): S20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. M. Weber, A. L. Scarim, and J. A. Corbett
Inhibition of IFN-gamma -induced STAT1 activation by 15- deoxy-Delta 12,14-prostaglandin J2
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E883 - E891.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. D. Molano, A. Pileggi, T. Berney, R. Poggioli, E. Zahr, R. Oliver, C. Ricordi, D. M. Rothstein, G. P. Basadonna, and L. Inverardi
Prolonged Islet Allograft Survival in Diabetic NOD Mice by Targeting CD45RB and CD154
Diabetes, April 1, 2003; 52(4): 957 - 964.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Garcia-Ocana, K. K. Takane, V. T. Reddy, J.-C. Lopez-Talavera, R. C. Vasavada, and A. F. Stewart
Adenovirus-mediated Hepatocyte Growth Factor Expression in Mouse Islets Improves Pancreatic Islet Transplant Performance and Reduces Beta Cell Death
J. Biol. Chem., January 3, 2003; 278(1): 343 - 351.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. Shapiro
Eighty years after insulin: parallels with modern islet transplantation
Can. Med. Assoc. J., December 10, 2002; 167(12): 1398 - 1400.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P.-O. Carlsson, F. Palm, and G. Mattsson
Low Revascularization of Experimentally Transplanted Human Pancreatic Islets
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5418 - 5423.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Hirshberg, S. Mog, N. Patterson, J. Leconte, and D. M. Harlan
Histopathological Study of Intrahepatic Islets Transplanted in the Nonhuman Primate Model Using Edmonton Protocol Immunosuppression
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5424 - 5429.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
L. Kessler, R. Passemard, J. Oberholzer, P. Y. Benhamou, P. Bucher, C. Toso, P. Meyer, A. Penfornis, L. Badet, P. Wolf, et al.
Reduction of Blood Glucose Variability in Type 1 Diabetic Patients Treated By Pancreatic Islet Transplantation: Interest of continuous glucose monitoring
Diabetes Care, December 1, 2002; 25(12): 2256 - 2262.
[Abstract] [Full Text] [PDF]